Table 1 Baseline patient characteristics
Characteristic | N = 855 |
|---|---|
Median age, years (range) | 61 (16–88) |
Male/female, n (%) | 460 (54)/395 (46) |
ECOG PS, n (%) | |
0 | 563 (66) |
1 | 267 (31) |
2 | 25 (3) |
Time from diagnosis, months (range) | 39 (3–280) |
Tumour subtype | |
Cutaneous | 631 (74) |
Mucosal | 71 (8) |
Ocular | 83 (10) |
Primary origin unknown | 70 (8) |
Patients with brain metastases, n (%) | 146 (17) |
Patients with liver metastases, n (%) | 339 (40) |
Elevated LDH (≥1.10 ULN), n/n (%) | 276/720 (38) |
BRAF-mutation positive, n/n (%) | 173/469 (37) |
NRAS-mutation positive, n/n (%) | 14/82 (17) |
Number of previous therapies: | |
1 | 497 (58) |
2 | 233 (27) |
≥3 | 125 (15) |
Previous therapy, n (%) | |
Dacarbazine | 490 (57) |
Fotemustine | 322 (38) |
Platinum-based chemotherapy | 316 (37) |
Paclitaxel | 78 (9) |
Temozolomide | 189 (22) |
Interferon | 192 (22) |
BRAF inhibitor | 59 (7) |